{
    "clinical_study": {
        "@rank": "58703", 
        "arm_group": [
            {
                "arm_group_label": "Evacetrapib -- Solid Fraction Test", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to two of three periods"
            }, 
            {
                "arm_group_label": "Evacetrapib -- Solid Fraction Reference", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to two of three periods"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to measure and compare the amounts of the study drug\n      evacetrapib found in the blood after taking two different formulations.  The study has 3\n      periods.  Participants will take each formulation by mouth at least once.  A minimum of 14\n      days will pass between study drug doses.  The safety and tolerability of the study drug will\n      also be examined.  Information about any side effects that may occur will also be collected.\n       This study will last approximately 6 weeks."
        }, 
        "brief_title": "A Study of Evacetrapib (LY2484595) in Healthy Participants", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male participants  agree to use a reliable method of birth control and not donate\n             sperm during the study and for 90 days after study completion\n\n          -  Female participants who are not of child-bearing potential due to surgical\n             sterilization confirmed by medical history, or menopause\n\n          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)\n\n          -  Are reliable and willing to make themselves available for the duration of the study\n             and are willing to follow study procedures\n\n        Exclusion Criteria:\n\n          -  Are currently enrolled in, or have completed or discontinued within the last 30 days\n             from, a clinical trial involving an investigational product\n\n          -  Have known allergies to evacetrapib, related compounds or any components of the\n             formulation, or history of significant allergic disease as determined by the\n             investigator\n\n          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine, hematological, or neurological disorders\n\n          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug\n             screening\n\n          -  Are women who are pregnant or lactating\n\n          -  Have used or intend to use over-the-counter or prescription medications (including\n             vitamins/mineral supplements, herbal medicine) 14 days prior to enrollment and during\n             the study\n\n          -  Have donated blood of more than 500 milliliter (mL) within the last month\n\n          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14\n             units per week (females), or are unwilling to stop alcohol consumption from 48 hours\n             prior to each dose and while resident at the Clinical Research Unit (CRU)\n\n          -  Currently smoke or use tobacco or nicotine products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903434", 
            "org_study_id": "14623", 
            "secondary_id": "I1V-MC-EIAU"
        }, 
        "intervention": {
            "arm_group_label": [
                "Evacetrapib -- Solid Fraction Test", 
                "Evacetrapib -- Solid Fraction Reference"
            ], 
            "description": "Administered orally", 
            "intervention_name": "Evacetrapib", 
            "intervention_type": "Drug", 
            "other_name": "LY2484595"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47710"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 168 hours post-dose for each period"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0-\u221e]) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 168 hours post-dose for each period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903434"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}